Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Wages, Salaries and Other
Others
Ratios

Nuvation Bio (NUVB) EBIT (2023 - 2025)

Nuvation Bio (NUVB) has disclosed EBIT for 3 consecutive years, with -$34.0 million as the latest value for Q4 2025.

  • On a quarterly basis, EBIT rose 36.9% to -$34.0 million in Q4 2025 year-over-year; TTM through Dec 2025 was -$213.1 million, a 64.05% increase, with the full-year FY2025 number at -$213.1 million, up 64.05% from a year prior.
  • EBIT was -$34.0 million for Q4 2025 at Nuvation Bio, up from -$56.4 million in the prior quarter.
  • In the past five years, EBIT ranged from a high of -$20.2 million in Q1 2024 to a low of -$470.4 million in Q2 2024.
  • A 3-year average of -$75.5 million and a median of -$41.1 million in 2024 define the central range for EBIT.
  • Peak YoY movement for EBIT: tumbled 1700.1% in 2024, then soared 86.48% in 2025.
  • Nuvation Bio's EBIT stood at -$20.8 million in 2023, then plummeted by 158.95% to -$53.9 million in 2024, then soared by 36.9% to -$34.0 million in 2025.
  • Per Business Quant, the three most recent readings for NUVB's EBIT are -$34.0 million (Q4 2025), -$56.4 million (Q3 2025), and -$63.6 million (Q2 2025).